FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility
UniQure is preparing to seek accelerated FDA approval for its Huntington’s disease gene therapy, a…
FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility
UniQure is preparing to seek accelerated FDA approval for its Huntington’s disease gene therapy, a move that follows the FDA’s reversal of its prior position calling for another clinical trial. This gene therapy is the latest in a growing list of rare disease treatments to receive reconsideration from an FDA that appears to be swinging…
Combined GI Procedures Are Becoming Routine – AI Can Help Address the Gap in Upper GI Quality Standards
Combined upper and lower GI endoscopy is becoming standard practice across many US healthcare settings, but the quality infrastructure for upper GI has not kept pace with the procedures now being performed on it. The post Combined GI Procedures Are Becoming Routine – AI Can Help Address the Gap in Upper GI Quality Standards appeared…
The Human Behind the Machine: Why Healthcare Must Resist the Rush To Automate
The healthcare organizations getting this right are not defined by how much they’ve automated. They are defined by how deliberately they’ve protected the human touchpoints that drive trust, engagement, and outcomes. The post The Human Behind the Machine: Why Healthcare Must Resist the Rush To Automate appeared first on MedCity News.
Leveraging Technology to Navigate the New Era of Continuous Organ Distribution
As air transportation for organs becomes more common, both in response to tech advancements and changing federal guidelines, the industry needs tools that synchronize communication between dispersed teams and can keep pace with air transport. The post Leveraging Technology to Navigate the New Era of Continuous Organ Distribution appeared first on MedCity News.
KFF Tracking Poll on Health Information and Trust: Use of Social Media and AI For Health Information and Advice
This poll finds that about 3 in 10 adults turn to social media for health information and advice at least monthly. Community connection and the need for immediate answers are the top reasons why people are turning to these tools. Slim majorities of those who use social media for health are confident they can tell…
Tennessee Pharmacies Sell Potent Ivermectin, Led by Anti-Vaccine Doctor Who’s Taken ‘Bucketloads’
NASHVILLE, Tenn. — Four years ago, Tennessee became the first state to allow adults to buy the antiparasitic drug ivermectin from a pharmacy without first seeing a doctor. Pharmacies can use a pre-written, blanket prescription to sell to just about anyone who walks through their doors. The drug is now marketed and sold across the…
Democrats Seek To Spotlight Rising Health Costs by Forcing Vote on Trump Regulation
In a move that mixes pure politics with weedy congressional procedures, Senate Democrats are seeking to force a vote to overturn a Trump administration rule that they say will make it harder to enroll in Affordable Care Act health plans and sharply raise out-of-pocket costs for those who do. The measure is unlikely to pass…
More Americans Are Surviving Cancer. But the Mental Health Challenges Can Persist.
The cancer diagnosis came as a shock, disrupting Morgan Newman’s plans for launching her life. It was 2015, and she was working as a dental assistant in Des Moines, Iowa, while studying to become a social worker. After an abnormal result on her Pap smear, her doctor brought her back in to check the tissue…
InStride Raises $30M to Scale Pediatric Mental Health Support
InStride’s Series C round includes support from new investors Echo Health Ventures and FMZ Ventures, as well as existing investors .406 Ventures, Valtruis, General Catalyst and Mass General Brigham Ventures. The post InStride Raises $30M to Scale Pediatric Mental Health Support appeared first on MedCity News.
New Cancer Biotech Unveils $27M for Dual-Targeting Prostate Cancer Drug
MultiValent Biotherapies is developing a peptide-like drug conjugate that hits two validated targets to treat prostate cancer. This clinical-stage asset was licensed from China-based Coherent Biopharma. The post New Cancer Biotech Unveils $27M for Dual-Targeting Prostate Cancer Drug appeared first on MedCity News.
